Back to top

crispr: Archive

Zacks Equity Research

CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates

CRISPR Therapeutics posts a narrower-than-expected Q3 loss, trims R&D spend, and advances late-stage and next-gen gene-editing programs.

ALKSNegative Net Change VRTXNegative Net Change CRMDPositive Net Change CRSPPositive Net Change

Sundeep Ganoria

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

VRTXNegative Net Change BEAMPositive Net Change NTLAPositive Net Change CRSPPositive Net Change